Clinical Trials Logo

Gastroduodenal Ulcer clinical trials

View clinical trials related to Gastroduodenal Ulcer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04123899 Not yet recruiting - Clinical trials for Gastroduodenal Ulcer

BE Study of Gaster®D Tab 20mg (Manufacturer Changed)

Start date: October 11, 2019
Phase: N/A
Study type: Interventional

An Open-Label, Randomized, Two-sequence, Two-period, Fasting Condition, Single Oral Dose, Cross-over Study of Bioequivalence of "Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)" and "Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)" in Healthy, Adult, Human Subjects.

NCT ID: NCT02882477 Not yet recruiting - Diabetes Mellitus Clinical Trials

Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy

Start date: December 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Patients who are genetically diagnosed with the recently reported and rare Wolfram syndrome type 2 ( WFS2) and have the degenerative and symptomatic disease including signs such as diabetes, platelet aggregation defect or visual problems will be asked to participate in this study. Knowing the pathomechanism of WFS2 with rapid cell death, after doing baseline investigations to asses the severity of their disease, the participants will be offered a chelator therapy with in addition to the antioxidant Acetylcystein, in diabetic patients an Incertin (GLP-1 ) therapy will be offered as well. The baseline investigations will be repeated after 2 months and after 5 months of therapy in order to asses the progression of the disease and to show if the chelator and anti oxidant therapy and in diabetic patients the GLP-1 therapy could stop the progression of the disease.